& Woolf, A
Investigation of the influence of FcRn on the distribution of IgG to the brain
Combining regular exercise with GLP-1 therapy is estimated to generate: United States : US$120 billion in economic and societal value over 10 years and a 496% return on investment, rising to 1,572% and US$393 billion over 30 years
The sub-30-minute half-life documented in preclinical research provides a pharmacokinetic rationale for twice-daily dosing
Seemingly contradictory, various previous studies on tumor cell lines ( NRF2 and HO-1 upon SFN treatment in both untransformed human T-cells (Supplementary Figure 5A) and prostate cancer PC-3 cells (Supplementary Figure 5B)
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
